If you have followed the Roundup news this year, you have seen three separate stories about Bayer getting some form of protection — a Supreme Court win, a farm bill provision, a presidential order — and it is easy to come away believing the door has closed on cancer survivors. It has not. Every one of these efforts aims at the same target: the product label. And the theory our firm has led with from the start was never built on the label.
Three Roads to the Same Destination
Corporate defendants facing mass litigation rarely rely on a single defense. In 2026, the effort to insulate Bayer from Roundup cancer claims has advanced on three fronts at once: through the courts, through Congress, and through the executive branch. Understanding them together — rather than reacting to each headline in isolation — is the only way to see what has actually changed for someone diagnosed with a glyphosate-linked cancer.
The common thread is a legal doctrine called federal preemption. The Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) is the federal pesticide law. It bars states from imposing labeling requirements "in addition to or different from" the requirements the U.S. Environmental Protection Agency enforces. Bayer's strategy, in the courtroom and in Congress, is to stretch that clause into a broad shield: if the EPA approved a label without a cancer warning, the argument goes, no state jury should be able to punish Monsanto for not adding one. Keep that idea in mind, because it is the hinge on which all three efforts turn — and its central weakness.
The Court Route: Monsanto v. Durnell
The first and most consequential development came from the Supreme Court. On June 25, 2026, in Monsanto Co. v. Durnell, the Court held 7-2 that FIFRA preempts a state-law failure-to-warn claim where the EPA evaluated the risk and approved a label that did not carry the warning the plaintiff said was required. Justice Brett Kavanaugh wrote for the majority; Justice Ketanji Brown Jackson, joined by Justice Neil Gorsuch, dissented. The ruling set aside a Missouri jury verdict that had been entered in John Durnell's favor.
We covered that decision in depth in our full analysis of the Durnell ruling. The short version bears repeating here because it frames everything that follows: Durnell decided one question about one theory. It did not declare Roundup safe, it did not overturn the science, and it expressly did not address design-defect, manufacturing-defect, or strict-liability claims that do not depend on the label's content. The Court narrowed the failure-to-warn road. It left the others open.
The Legislative Route: Farm Bill Section 10205
What the industry could not fully secure in court, it has also sought from Congress. On February 13, 2026, House Republicans unveiled a draft farm bill containing a provision, Section 10205, that would have mandated a uniform national pesticide label. In plain terms, it would have prevented state and local governments from requiring health and safety warnings that depart from the label the EPA registers — and, critically, from holding a manufacturer liable for failing to give such a warning. That is a legislative version of the same label shield at issue in Durnell, but broader and permanent.
The provision drew organized opposition. Representatives Chellie Pingree (D-Maine) and Thomas Massie (R-Kentucky) introduced a bipartisan amendment to strip it out. As Pingree framed the stakes, "Big Chemical has spent years trying to buy exactly this kind of protection from Congress: immunity from lawsuits, weaker safeguards, and a federal override of state and local pesticide protections." Supporters included the Bayer-led Modern Ag Alliance, a coalition of roughly 110 agricultural organizations, and House Agriculture Committee Chairman Glenn Thompson (R-Pennsylvania). Advocates from the "Make America Healthy Again" movement rallied against it under the banner "People vs. Poison."
The amendment to remove the provision passed 280-142. The House then passed the farm bill without it, by a narrower 224-200. As of this writing, no federal statute grants pesticide manufacturers immunity from failure-to-warn liability of this kind.
The Executive Route: The Glyphosate Production Order
The third front is the executive branch. On February 18, 2026, President Trump signed an executive order titled "Promoting the National Defense by Ensuring an Adequate Supply of Elemental Phosphorus and Glyphosate-Based Herbicides." It invokes the Defense Production Act and directs the Secretary of Agriculture to prioritize the domestic supply of glyphosate and the elemental phosphorus used to make it, framing the matter as one of national security.
It is important to read that order for what it is. It is a production and supply-chain directive, not a grant of blanket immunity from personal-injury lawsuits. It signals the administration's alignment with the industry on glyphosate, and legal commentators have noted the Defense Production Act carries its own limited liability protections for contractors filling government orders. But an executive order cannot rewrite the tort law of fifty states, and it does not by itself extinguish a survivor's product-liability claim. The Environmental Working Group and other watchdogs have criticized the combined effect of the order and the Durnell ruling, but criticism of the policy direction is not the same as a closed courthouse door.
The Counter-Move: The Pesticide Injury Accountability Act
The preemption effort has not gone unanswered in Congress. In July 2025, Senator Cory Booker (D-New Jersey) introduced the Pesticide Injury Accountability Act (S.2324 in the 119th Congress). It would move in the opposite direction from Section 10205: rather than shield manufacturers, it would amend FIFRA to create a federal right of action, allowing a person injured by a pesticide to sue the registrant in federal court, and it states expressly that it would not preempt any state-law claim.
The bill sits in the Senate Committee on Agriculture, Nutrition, and Forestry, and observers give it little near-term chance of passage. We mention it not as a prediction but because it illustrates the real state of the law: preemption is contested, not settled. Congress has both a bill that would expand the shield and a bill that would dismantle it, and neither has become law. Anyone who tells you the question is finished is overstating the record in one direction or the other.
Why a Label Shield Does Not End Roundup Cases
Here is the point that ties all three efforts together, and the reason we are not treating 2026 as the end of Roundup litigation. Every one of these measures — the Durnell holding, farm bill Section 10205, the executive order's regulatory posture — is aimed at the label. They are about what warning the product was or was not required to carry.
The theory The Alvarez Law Firm has emphasized from the beginning is different. It is strict product liability based on design defect: the argument that the product was unreasonably dangerous as formulated, and that the science Monsanto possessed about it made it so, regardless of what any label said. A design-defect claim does not rise or fall on whether the EPA required a cancer warning. It asks whether the formulation itself — not the wording on the jug — was defective. This is the same defective-product framework the firm has used against other manufacturers, and it is the reason our Roundup cases were never built solely on the warning.
That distinction was a matter of strategy before 2026. It now looks structural. A shield built around the label, by its own terms, does not reach a claim that never depended on the label. The Supreme Court did not decide the design-defect question in Durnell. Section 10205 did not become law, and even its text was addressed to labeling and failure-to-warn liability. And an order about glyphosate production says nothing about whether a specific formulation was defectively designed.
We want to be precise, because Roundup coverage tends toward hype in both directions. None of this is a guarantee about any individual case. Whether a case can move forward after Durnell, and under whatever the law becomes, depends on the facts: the diagnosis, the exposure history, the products used, and the theories available under the law of the relevant state. That is a case-by-case question, not a headline.
What This Means If You Were Diagnosed With a Roundup-Linked Cancer
Several practical points follow from the year's developments.
- Do not read the headlines as a verdict on your case. "Supreme Court sides with Monsanto" and "Trump backs glyphosate" describe the label fight and the policy climate. Neither decides whether a design-defect or strict-liability theory fits your facts.
- The diagnosis and exposure records matter more than ever. A well-documented exposure history and a clearly established qualifying diagnosis — such as non-Hodgkin lymphoma and its subtypes — are the foundation of a case under any surviving theory.
- The EPA's actual evaluation is a live issue. Because a label shield depends on the EPA having genuinely evaluated the specific cancer risk, the long-running disagreement between IARC and the EPA on glyphosate is more central to the litigation than ever.
- Deadlines have not paused for the politics. Every state has a filing deadline, and the legislative and legal landscape shifting does not stop your statute of limitations from running. Our guide on who qualifies for a Roundup lawsuit walks through what we evaluate.
Frequently Asked Questions
Has Congress given Bayer immunity from Roundup lawsuits?
No. A provision in the 2026 House farm bill draft, Section 10205, would have required a uniform national pesticide label and barred states from holding manufacturers liable for failing to give a warning the EPA never required. The House removed that provision by a 280-142 vote on an amendment led by Representatives Chellie Pingree and Thomas Massie, and passed the farm bill without it, 224-200. As of now, no federal statute grants pesticide makers immunity from these claims. Whether Congress revisits the idea is an open question.
Does Trump's glyphosate executive order shield Bayer from cancer lawsuits?
The executive order signed February 18, 2026 directs increased domestic production of glyphosate and elemental phosphorus and invokes the Defense Production Act, citing national security. It is a production and supply-chain order, not a grant of blanket immunity for personal-injury lawsuits. It signals the administration's support for the industry, but it does not by itself extinguish a survivor's product-liability claim.
If the EPA-approved label is protected, can I still sue over Roundup?
A label shield — whether from a court decision like Monsanto v. Durnell or from proposed legislation — targets the failure-to-warn theory, which argues the label should have carried a cancer warning. It does not, by its terms, reach a design-defect or strict-liability claim that the product was unreasonably dangerous as formulated, regardless of the label. Those theories were not decided in Durnell and are not what the farm bill provision addressed. Whether a specific case can proceed depends on its facts and the theories available under the relevant state's law.
What is the Pesticide Injury Accountability Act?
It is a bill introduced by Senator Cory Booker in July 2025 (S.2324, 119th Congress) that would amend FIFRA to create a federal right of action, allowing a person injured by a pesticide to sue the manufacturer in federal court and expressly stating that it would not preempt state-law claims. It sits in the Senate Committee on Agriculture, Nutrition, and Forestry, and commentators consider its near-term passage unlikely. It is the legislative counterweight to the preemption effort.
Bottom Line
2026 has been the most active year in memory for efforts to protect Bayer from Roundup liability — a Supreme Court ruling, a farm bill provision, and a presidential order, all pointing the same direction. But when you line them up, they share a boundary. Each is aimed at the product label and the duty to warn. None of them decided whether Roundup was defectively designed, and none of them closed the door on the strict-liability theory our firm has always led with. If you or a family member used Roundup and were later diagnosed with Non-Hodgkin Lymphoma, B-cell Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma, the right response to a confusing news year is not to assume the door is shut — it is to have your records read carefully under the theories that survive.
At our firm, Herb Borroto, M.D., J.D., reads the pathology, the immunohistochemistry, and the oncology charts himself, and Alex Alvarez, Managing Partner and Board Certified Civil Trial Lawyer, evaluates the legal theory each case can support. The free case review is exactly what it says: no obligation, and no fee unless we recover for you.